100 years of glucagon and 100 more
NJ Wewer Albrechtsen, JJ Holst, AD Cherrington… - Diabetologia, 2023 - Springer
The peptide hormone glucagon, discovered in late 1922, is secreted from pancreatic alpha
cells and is an essential regulator of metabolic homeostasis. This review summarises …
cells and is an essential regulator of metabolic homeostasis. This review summarises …
Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy
J Goldney, JA Sargeant, MJ Davies - Diabetologia, 2023 - Springer
Glucagon-like peptide-1 receptor agonists (GLP-1RAs, incretin mimetics) and dipeptidyl
peptidase-4 inhibitors (DPP-4is, incretin enhancers) are glucose-lowering therapies with …
peptidase-4 inhibitors (DPP-4is, incretin enhancers) are glucose-lowering therapies with …
Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study
S Piccini, G Favacchio, C Panico, E Morenghi… - Cardiovascular …, 2023 - Springer
Background Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown
cardiovascular benefits in cardiovascular outcome trials in type 2 diabetes mellitus …
cardiovascular benefits in cardiovascular outcome trials in type 2 diabetes mellitus …
Role of Glucagon‐Like Peptide‐1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity
ED Michos, F Lopez‐Jimenez… - Journal of the American …, 2023 - Am Heart Assoc
Obesity remains a major public health problem, affecting almost half of adults in the United
States. Increased risk of cardiovascular disease (CVD) and CVD mortality are major obesity …
States. Increased risk of cardiovascular disease (CVD) and CVD mortality are major obesity …
First-phase insulin secretion: can its evaluation direct therapeutic approaches?
G Di Giuseppe, G Ciccarelli, L Soldovieri… - Trends in Endocrinology …, 2023 - cell.com
Our work is aimed at unraveling the role of the first-phase insulin secretion in the natural
history of type 2 diabetes mellitus (T2DM) and its interrelationship with insulin resistance …
history of type 2 diabetes mellitus (T2DM) and its interrelationship with insulin resistance …
Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been used to treat patients
with type 2 diabetes since 2005 and have become popular because of the efficacy and …
with type 2 diabetes since 2005 and have become popular because of the efficacy and …
In vivo mapping of hemodynamic responses mediated by tubuloglomerular feedback in hypertensive kidneys
The kidney has a sophisticated vascular structure that performs the unique function of
filtering blood and managing blood pressure. Tubuloglomerular feedback is an intra …
filtering blood and managing blood pressure. Tubuloglomerular feedback is an intra …
Type 2 diabetes and cardiovascular disease: risk reduction and early intervention
D Hinnen, D Kruger, M Magwire - Postgraduate medicine, 2023 - Taylor & Francis
People with type 2 diabetes (T2D) have a higher risk of cardiovascular (CV) disease (CVD)
than those without. This increased risk begins with pre-diabetes, potentially 7–10 years …
than those without. This increased risk begins with pre-diabetes, potentially 7–10 years …
Biology and clinical use of glucagon-like-peptide-1 receptor agonists in vascular protection
Abstract Glucagon-like-peptide-1 receptor agonists (GLP1RA) are incretin agents initially
designed for the treatment of type 2 diabetes mellitus but due to pleiotropic actions are now …
designed for the treatment of type 2 diabetes mellitus but due to pleiotropic actions are now …